N
Noa Lowenton-Spier
Researcher at Harvard University
Publications - 6
Citations - 75
Noa Lowenton-Spier is an academic researcher from Harvard University. The author has contributed to research in topics: Randomized controlled trial & Bevacizumab. The author has an hindex of 2, co-authored 5 publications receiving 47 citations.
Papers
More filters
Journal ArticleDOI
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Timothy F. Cloughesy,Andrew Brenner,John de Groot,Nicholas Butowski,Leor Zach,Jian Campian,Benjamin M. Ellingson,Laurence S. Freedman,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Shifra Fain Shmueli,Patrick Y. Wen +12 more
TL;DR: In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM and change of treatment regimen, with the lack of Vb-111 monotherapy priming, may explain the differences from the favorable phase II results.
Journal ArticleDOI
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Andrew Brenner,Katherine B. Peters,James J. Vredenburgh,Felix Bokstein,Deborah T. Blumenthal,Shlomit Yust-Katz,Idit Peretz,Bernice Oberman,Laurence S. Freedman,Benjamin M. Ellingson,Timothy F. Cloughesy,Naamit Sher,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Niva Yakov,Itzhak Mendel,Eyal Breitbart,Patrick Y. Wen +18 more
TL;DR: Patients with rGBM who were primed with VB-111 monotherapy that continued after progression with the addition of bevacizumab showed significant survival and PFS advantage, as well as specific imaging characteristics related to Vb-111 mechanism of action.
Journal ArticleDOI
Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
Richard T. Penson,Kathleen N. Moore,Thomas J. Herzog,Robert A. Burger,Laurence S. Freedman,Noa Lowenton-Spier,Dror Harats,Naamit Sher,Yael C Cohen,Bradley J. Monk +9 more
TL;DR: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism: an antiangiogenic broad effect and induction of a tumor directed viral immune respon...
Journal ArticleDOI
Atim-19. results of the globe study: a phase 3, randomized, controlled, double-arm, open-label, multi-center study of vb-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma
Timothy F. Cloughesy,Andrew Brenner,Nicholas Butowski,Yael C Cohen,Noa Lowenton-Spier,Patrick Y. Wen +5 more
Journal ArticleDOI
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Benjamin M. Ellingson,Kunal S. Patel,Chencai Wang,Catalina Raymond,Andrew Brenner,John de Groot,Nicholas Butowski,Leor Zach,Jian Campian,Jacob Schlossman,Shan Rizvi,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Shifra Fain Shmueli,Patrick Y. Wen,Timothy F. Cloughesy +16 more
TL;DR: In this paper, the authors used diffusion MRI and ADCL as independent imaging biomarkers of OS in recurrent glioblastoma (rGBM) patients treated with bevacizumab (BV) versus BV+VB-111, an anti-cancer viral therapy.